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Abstract 
Background: Peripheral nerve injury and bone lesions, well known leprosy complications, lead to deformities and 
incapacities. The phosphate-regulating gene with homologies to endopeptidase on the X chromosome (PHEX) 
encodes a homonymous protein (PHEX) implicated in bone metabolism. PHEX/PHEX alterations may result in bone 
and cartilage lesions. PHEX expression is downregulated by intracellular Mycobacterium leprae (M. leprae) in cultures of 
human Schwann cells and osteoblasts. M. leprae in vivo effect on PHEX/PHEX is not known.
Methods: Cross-sectional observational study of 36 leprosy patients (22 lepromatous and 14 borderline-tuberculoid) 
and 20 healthy volunteers (HV). The following tests were performed: PHEX flow cytometric analysis on blood mono-
nuclear cells, cytokine production in culture supernatant, 25-hydroxyvitamin D (OHvitD) serum levels and 99mTc-MDP 
three-phase bone scintigraphy, radiography of upper and lower extremities and blood and urine biochemistry.
Results: Significantly lower PHEX expression levels were observed in lepromatous patients than in the other groups 
(χ2 = 16.554, p < 0.001 for lymphocytes and χ2 = 13.933, p = 0.001 for monocytes). Low levels of 25-(OHvitD) were 
observed in HV (median = 23.0 ng/mL) and BT patients (median = 27.5 ng/mL) and normal serum levels were found 
in LL patients (median = 38.6 ng/mL). Inflammatory cytokines, such as TNF, a PHEX transcription repressor, were lower 
after stimulation with M. leprae in peripheral blood mononuclear cells from lepromatous in comparison to BT patients 
and HV (χ2 = 10.820, p < 0.001).
Conclusion: Downregulation of PHEX may constitute an important early component of bone loss and joint damage 
in leprosy. The present results suggest a direct effect produced by M. leprae on the osteoarticular system that may use 
this mechanism.
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Background
Bone disease occurs in many clinical conditions, from 
infectious to metabolic, inflammatory, cancer and genetic 
disorders. Among the infectious diseases, leprosy, caused 
by Mycobacterium leprae, is widely known because of 
the acral deformities. Lepromatous leprosy (LL) is one 
of the polar forms of the spectrum of the disease, in 
which patients exhibit high bacillary load, numerous 
skin lesions and hypo-responsiveness to M. leprae. At 
the opposite end of the spectrum, the polar tuberculoid 
patients (TT) and borderline tuberculoid (BT) show 
reduced bacillary load (undetectable in slit-skin smear), 
few cutaneous lesions and pathogen-specific cellular 
immune response [1].
The prevalence of bone damage is variable accord-
ing to the casuistic evaluated. In a retrospective cohort 
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of 105 newly-diagnosed adult multibacillary leprosy 
patients surveyed for up to 8  years after release from 
treatment, 23 % of the patients were found to have acral 
resorption [2]. Also, in patients with established dis-
ability, bone damage was found to be present in 80 % of 
patients [3]. The small bones of hands and feet are the 
most affected, followed in frequency by facial bones [4, 
5]. In the affected bones, M. leprae-filled macrophages 
can be observed in the medullar cavity and trabecu-
lar bone destruction [4]. Signs of periostitis, different 
degrees of phalange resorption, bone cysts, trabecu-
lation loss and osteoporosis can be observed in image 
studies [3, 6].
The X-linked hypophosphatemic rickets is a rare dis-
ease that produces deficient bone matrix mineralization 
resulting in rickets or osteomalacia, hypophosphatemia, 
and changes in vitD metabolism [7]. It is caused by the 
absence of phosphate-regulating gene with homologies to 
endopeptidase on the X chromosome (PHEX) [8].
How can these two diseases be related? Reduction of 
PHEX transcription and protein expression (PHEX) was 
found to be produced by M. leprae in cultured Schwann 
cells and human osteoblasts [9]. PHEX binds to the small 
integrin-binding ligand, N-linked glycoprotein (SIB-
LING) family of proteins and participates in a complex 
pathway that modulates bone matrix mineralization, 
phosphate renal excretion, serum levels of fibroblast 
growth factor 23 (FGF23) and 1,25(OH)2vitamin D regu-
lation [10–20]. Could this mechanism induce bone dam-
age in lepromatous patients? To answer this question we 
evaluated PHEX expression, its possible regulatory medi-




This case series study was developed at the Leprosy Lab-
oratory and Souza Araújo Outpatient Unit of Oswaldo 
Cruz Institute, Fiocruz, and the Santa Casa de Miser-
icórdia Hospital, in Rio de Janeiro, Brazil. A total of 36 
newly-diagnosed untreated patients (22 LL and 14 BT) 
were evaluated. In addition, 20 healthy volunteers (HV), 
selected from medical and laboratory staff were included 
as negative controls for the assessment of the immune 
response against M. leprae and VitD measurements 
(Fig. 1).
The leprosy patients followed routine examinations 
and were classified according to the Ridley and Jopling 
criteria [1]. The disability grade resulting from the pres-
ence of neurological signs and symptoms in the patients’ 
eyes, hands and feet was registered by a physiothera-
pist [21]. The bacillary index (BI) was obtained from the 
slit-skin smear of six sites. The project was approved by 
the Oswaldo Cruz Foundation Research Ethics Commit-
tee, protocol number 205/03.
In vitro tests
Peripheral blood mononuclear cells (PBMC) from LL, BT 
and HV were isolated over ficoll-hypaque (GE Health-
care, UK) by density gradient centrifugation, washed in 
PBS, and divided into two parts, one for the flow cytom-
etry study, the other part for the cytokine production 
assay.
Flow cytometry
In order to detect PHEX surface expression, PBMCs were 
re-suspended in flow cytometry buffer and incubated 
with anti-PHEX purified followed by a fluorescein isothi-
ocyanate labeled polyclonal antibody (FITC; Alpha Diag-
nostic International, Inc., USA) as secondary marker. For 
T cell and monocyte identification, the cells also were 
marked with anti-CD3-phycoerythrin and anti-CD14-
cychrome monoclonal antibodies (BD Biosciences, 
USA). Following incubation, the cells were analyzed in a 
FACSCalibur flow cytometer (BD Biosciences, USA), as 
described [22].
Cytokine production assay
PBMC were re-suspended in the AIM-V culture medium 
(106 cells/mL), and cultured for 5 days in 96-well round-
bottom culture plates (2  ×  105 cells/well; Corning Inc. 
Life Sciences, USA). TNF, IL-1β and IFN-γ levels were 
measured in the culture supernatants collected from 
unstimulated and 20 µg/mL whole-irradiated M. leprae-
stimulated cultures (provided from Colorado State Uni-
versity, USA through the NIH/NIAID “Leprosy Research 
Support” contract N01 AI-25469) and 1 μg/mL Staphy-
lococcal Enterotoxin B (SEB; Sigma Chemical Co., St. 
Louis, MO, USA). The cytokines levels were measured 
using a multiplex kit (Lincoln-Millipore, EMD Millipore, 




The hands and feet of a subgroup of 5 LL patients were 
studied by conventional X-ray. In addition, computed 
radiography digital X-ray antero-posterior skiagrams 
were obtained of the hands to look for more detailed 
bone changes. The radiographs were analyzed  by  two 
experienced radiologists for the presence of specific and 
non-specific bone alterations. Findings were decided in 
consensus. Radiological bone resorption was defined 
as partial or total loss of one or several phalanges or 
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metatarsal or carpal bones; specific osteolysis was 
defined as a break in the contour (cortex and subcorti-
cal areas of the epiphyses) of the distal phalanx into 
bushy and berry-like lesions, and concentric absorption 
(longitudinal loss of the diaphysis) and distal absorp-
tion as non-specific osteolysis. Three-phase bone scin-
tigraphy was performed after intravenous injection of 
555–1110  mBq (15–30  mCi) of 99mTechnetium-meth-
ylene diphosphonate (99mTc-MDP) using a low-energy, 
high-resolution collimator (E.CAM, Siemens) in the 
same five patients. After injection of the radiophar-
maceutical, 2-s images of the hands were immediately 
obtained in a 64 × 64 matrix. Blood pool images of both 
the hands and feet were acquired 5–10 min after admin-
istration of 99mTc-MDP and stored in a computer via a 
128 × 128 matrix. Delayed anterior and posterior whole 
body images were used to determine the extent and dis-
tribution of the alterations. The third-phase images were 
acquired between 3–5 h and included spot images of the 
hands, feet, and other regions with alterations in the WB 
images. All spots were acquired in about 4–5 min using 
a 256 × 256 matrix.
Laboratory analysis
Venous blood and 24-h urine samples were col-
lected in these LL patients. The serum levels of alka-
line phosphatase, albumin, calcium, phosphorus, 
parathyroid hormone (PTH), parathyroid hormone-
related protein (PTHrP), pro-collagen type I, osteocal-
cin, and 1,25(OH)2vitamin D (high performance liquid 
chromatography) were measured. The levels of calcium, 
phosphorus, protein, N-telopeptide, pyridinoline and 
desoxypyridinoline were evaluated in the urine sam-
ples. Serum samples were obtained from additional 32 
individuals (12 LL, 9 BT and 11 HV) for determination 
of 25-vitD levels by quimioluminescence. This group of 
subjects were included after the first five LL patients were 
evaluated because low levels of this vitamin D3 metab-
olite is considered a risk factor for the development of 
various diseases and, in order to reduce the effect of envi-
ronmental variables, the same time interval was needed.
Statistical analysis
The statistical analysis was done using SPSS® 16. Due to 
the small sample number and non-gaussian distribution, 
Fig. 1 Study design. Groups of individuals evaluated and tests performed. A total of 36 patients and 20 healthy volunteers were clinically and/or 
laboratory assessed
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nonparametric tests were used to compare variables, 
including outliers and extreme values. Significance level 
was established at 95  %. The differences in the levels of 
cytokines, 25-(OH) vitD and PHEX expression were 
evaluated using the Kruskal–Wallis Chi square (KW-χ2), 
and the Mann–Whitney test. Graphs were done using the 
Prism 6.0 software (GraphPad Software Inc., USA).
Results and discussion
Fourteen BT patients (nine males) had a mean age of 37 years 
(range 15–58 years) and negative BI, except for one patient 
with 0.25log. Twenty two LL patients (17 male) were in aver-
age 50.3 years old (from 29–82 years) had a BI ranging from 
1.25 to 6.0 (median = 4.25). The twenty one HV were young 
adults (six males) from 19 to 52 years old (mean = 31 years).
Ex vivo study: PHEX expression in PBMC and cytokine 
production
PHEX expression was significantly lower in LL as com-
pared to BT patients and HV (Fig. 2) in both monocytes 
(KW-χ2  =  13,933, p  =  0.001) and lymphocytes (KW-
χ2  =  16,554, p  <  0.0001). This observation suggests a 
negative modulation of PHEX expression by the large 
quantity of mycobacteria present in LL patients. Once 
the downregulation of PHEX expression was observed, 
we sought to determine the production of inflammatory 
cytokines by M. leprae-stimulated blood leukocytes. TNF 
is known to modulate the PHEX transcription [23]. In 
addition, TNF intervenes in the host defense against M. 
leprae, and is low in LL patients [24, 25]. Cytokine pro-
duction by blood leukocytes in response to M. leprae was 
detected in most LL and BT patients’ and HV’s samples 
(Fig. 3).
Due to specific M. leprae hypo-responsiveness in LL 
patients, the expected low production levels of pro-
inflammatory cytokines were observed in these patients. 
TNF and IFN-γ levels were significantly lower in LL 
patients as compared to the other two groups (KW-
χ2 = 10.820, p < 0.001; KW-χ2 = 9.397, p = 0.003), and 
IL-1β production was similar in the three groups (KW-
χ2 = 0.483, p = 0.799). As expected, all SEB-stimulated 
cells (positive control) demonstrated high levels of TNF, 
IL-1β and IFN-γ production (data not shown). Therefore, 
the observed reduced PHEX expression in this set of LL 
patients was not related to the in vitro TNF production 
of the M. leprae-stimulated blood leukocytes. This find-
ing suggests that TNF may not be involved in the PHEX 
downregulation observed in LL patients.
In vivo study
Five LL patients (19–37 years old) were selected for clini-
cal, radiological, bone scintigraphy and metabolic evalua-
tion. Young adults were selected to exclude bone or joint 
changes as well as laboratory alterations due to the aging 
process. Three patients, all with BI higher than 4.0, had 
radiological changes and bone resorption (Additional 
file 1: Table S1). First-phase scintigraphy was abnormal in 
4 of the patients, who showed blood flow asymmetry and 
blood-pool alterations in the lower and upper extremi-
ties. Increased bone uptake of 99mTc-MDP was found in 
the hands or feet of all five patients. A bilateral involve-
ment was observed but the right extremities were more 
frequently affected. The distal phalange alterations dem-
onstrated by X-ray imaging (Fig. 4a, b) suggest long-term 
resorption thus 99mTC-MDP uptake is reduced in these 
areas (Fig. 4c). However, in other areas mainly the joints, 
hyper-fixation indicated more recent activity (Fig.  4c, 
d). Important joint alterations were also evidenced in 
all patients. Increased uptake was seen on the inter-
phalangeal joints, distal phalanges of the hands, meta-
carpal bones and/or wrists. The metacarpophalangeal 
and metatarsophalangeal joints were the most severely 
affected, followed by the intercarpal and the proximal 
Fig. 2 PHEX expression in T lymphocytes and monocytes by flow 
cytometric analysis. a Example of a flow cytometry result compar-
ing PHEX protein expression in lymphocytes (upper) and monocytes 
(lower) of a healthy volunteer (left) a lepromatous patient (right). The 
arrows show that the fluorescence median values were lowest in the 
patient. b Flow cytometry analysis of peripheral blood leukocytes of 
LL (n = 10), BT patients (n = 5) and healthy volunteers (n = 10) show-
ing a decrease in PHEX protein expression in LL patients (*p < 0.05)
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interphalangeal articulations in the hands. All patients 
presented normal serum levels of alkaline phosphatase, 
albumin, calcium, phosphorus, 1,25(OH)2vitamin D, 
PTHrP, in addition to normal urinary calcium, phos-
phorus, and protein levels. Parathyroid hormone dosage 
was normal (7–53 pg/mL) in all but one patient (91 pg/
mL, Additional file  1: Table S1, patient A). This patient 
also exhibited elevated blood levels of type I procollagen 
(162  ng/mL) and osteocalcin (68.8  ng/mL), including 
higher levels of N-telopeptide in the urine (244 nmBCE/
nmol). The levels of pyridinoline and deoxypyridinoline 
in the urine were also the most elevated among the 
patients, indicating a high-turnover bone disease. Miss-
ing samples or shorter time interval for the 24-h urine 
collection were suspected in patients C and D, taking into 
account their low levels of urinary creatinine excretion. 
Despite the missing samples in the 24-h urine collection, 
the elevation of the urinary collagen degradation prod-
ucts, still suggested increased bone resorption in these 
patients, as shown by the radiography and scintigraphy 
images (Additional file 1: Table S1). Interestingly, patients 
with higher levels of PHEX exhibited no alterations in 
radiographies, and fewer alterations in scintigraphy than 
patients with low PHEX expression.
Low vitD levels are found in a wide range of the world 
population. In Brazil it has been observed in about 60 % 
of the adolescent population [26] and 80 % of the adults 
in the Amazon region [27]. This vitamin is important for 
the immune system. It participates in the defense against 
mycobacteria by stimulating cathelicidin synthesis, both 
in macrophages and in dendritic cells [28, 29] as well as 
in keratinocytes [30]. Inhibition of the vitD-dependent 
microbicidal pathway has been shown in LL patients [31]. 
Therefore, we hypothesized that leprosy patients, espe-
cially those with LL form, would have vitD deficiency, 
because of their reduced cellular response against M. 
leprae. However, we only found two patients with lev-
els within the insufficiency range and two with vitamin 
deficiency (<20 ng/mL). Taking the value of 30 ng/mL as 
the lower normal serum value, no deficit was observed 
in the group of LL patients (mean  =  35.3  ±  12.7  ng/
mL, 95 % CI 27.19–43.36). BT patients had around nor-
mal levels of vitD (mean = 29.4 ± 10.6 ng/mL, 95 % CI 
21.22–37.49), but six patients were classified as insuf-
ficient and one was considered deficient. Interestingly, 
only 3 out of the 11 HV (27 %) had normal vitD serum 
levels (mean = 23.5 ± 8.4 ng/mL, 95 % CI 17.85–29.13), 
four had insufficient levels and four were in the deficient 
range. This finding was similar to other studies in which 
Fig. 3 Multiplex analysis of TNF (a), IL-1β (b) and IFN-γ (c) levels in 5-day culture supernatants. The results reflect cytokine levels in M. leprae-stim-
ulated cultures subtracted from unstimulated cultures. The three inflammatory cytokines were significantly lower in LL patients (n = 5) compared 
to BT patients (n = 5; *p < 0.05). All cytokines were produced in response to SEB (data not shown). IFN-γ levels in LL patients were also significantly 
lower in comparison to healthy volunteers (n = 5; *p < 0.05). Dotted-lines indicate established positive production levels in relation to negative 
controls
Fig. 4 Newly diagnosed lepromatous patients exhibits bone and 
cartilage lesions. a, b Radiography of left hand and foot. Asterisks 
indicate the distal phalanx erosion, typical hallmark of leprosy. c Third-
phase bone scintigraphy image shows increased bone uptake of 
99mTc-MDP in both hands. Hyper-fixation occurred in bones and joints 
of phalanges, metacarpus and wrists. Important joint alterations 
were evidenced in all patients. d The early phase scintigraphy shows 
localised radiotracer activity on the wrists
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high percentages of vitD insufficiency/deficiency in 
healthy controls, especially those from medical or labora-
tory staff [32]. Also, no difference in 25-(OH) vitD levels 
has been observed in patients with multibacillary leprosy 
as compared to healthy individuals [33].
As a whole, the patients had significantly higher vitD 
levels (χ2 =  6.774, p =  0.034) than the HV. Although 
at the onset of infection, low host vitD levels could 
be advantageous for M. leprae, impairing the vitD-
dependent microbicidal pathway, once the mycobac-
teria escape the host’s initial response, and long-term 
persistence in macrophages and Schwann cells is 
established, the presence of vitD could then hinder the 
elimination of pathogens due to its immunomodula-
tory effects. VitD could participate in the change of the 
response of Th1 lymphocytes to Th2 cells, and in the 
modulation of the macrophage differentiation from M1 
to M2 [31, 34].
Bone damage has for long been observed in LL patients 
[4, 35]. It has been attributed to the effect of abnormal 
serum electrolytes, peripheral neuropathy, local trauma, 
inflammation, hypogonadism [36], prolonged rest and 
malnutrition, or prolonged use of glucocorticoids to con-
trol reactional episodes [37, 38]. In the present study, the 
LL patients showed no detectable differences in serum 
electrolytes in comparison to the BT patients, had no evi-
dence of malnutrition and had not been treated with cor-
ticosteroids. Similarly, bone disease has been observed 
in leprosy patients with none of these risk factors [2]. 
Which mechanism could explain bone disease in such 
patients?
Peripheral neuropathy is a common finding in leprosy 
because of the M. leprae tropism to infect Schwann cells. 
It is more common in multibacillary than in paucibacil-
lary patients [39]. Some degree of peripheral neuropathy 
was observed in the five patients evaluated with radiog-
raphy and scintigraphy, two had hand, feet and/or facial 
hypo or anaesthesia, and three had deformities or perma-
nent disability. However, this finding could not explain all 
of the bone and joint lesions observed in these patients. 
Bone changes in patients with disabilities and deformi-
ties have characteristic features not observed in the five 
patients [3].
The physiopathology of peripheral neuropathy as a 
cause of acral deformities is well explained by the Charcot 
neuro-arthropathy, which is frequently seen in longstand-
ing diabetic patients [40]. This factor clearly explains 
deformities of the lower extremities, which are under the 
influence of body weight and locomotion micro-traumas. 
However, leprosy patients have bone and joint damage in 
upper extremities and the face, which are not observed in 
the diabetic patients, who suffer from glove and stocking 
neuropathy. In addition, specific bone changes have been 
found to be significantly increased in patients with absent 
or incomplete anti-leprosy treatment [3]. Interestingly, 
in a murine model of M. leprae, the infection directly 
caused bone damage in the infected mice that had bilat-
eral rear-limb palsy [41].
PTHrP, PTH [42] and 1,25(OH)2vitamin D [43, 44] 
produce negative regulation of PHEX transcription. 
However, we found no change in serum PTHrP or 
1,25(OH)2vitamin D in the subgroup of patients evalu-
ated, and only one of the patients had increased levels of 
parathyroid hormone. TNF is another negative modula-
tor of PHEX [45] and is a known risk factor for decreased 
bone mineral density in chronic inflammatory bowel dis-
ease [23]. The stimulation of PBMC by M. leprae in cell 
cultures did not result in increased production of TNF.
Once the inflammatory mediator production in 
response to M. leprae or vitD deficiency could not con-
tribute to the altered PHEX expression in the patients 
evaluated, a direct effect of M. leprae becomes a plausi-
ble cause. The downregulation of PHEX can contribute 
to the osteoarticular lesions observed in patients, as it 
would result in greater amounts of ASARM peptides able 
to directly inhibit the mineralization of the bone matrix 
[10, 11, 15]. In addition, PHEX decay and increase of 
ASARM peptides would favor the survival of osteocytes, 
inhibiting surrounding mineralization [18]. This would 
be advantageous to M. leprae survival, allowing the main-
tenance/proliferation of infected cells in bone, where pre-
vious studies have found bacilli [46].
Conclusions
The present was an exploratory study to evaluate a pos-
sible role of PHEX in bone alterations in leprosy, already 
shown in other diseases [10, 11, 15, 18]. Based on our 
previous findings on the negative modulation of PHEX 
in human osteoblast lineage [9], and the observed in 
blood leukocytes obtained from patients with lepro-
matous leprosy, we suggest that PHEX downregula-
tion may be a possible mechanism by which M. leprae 
directly affect bone. Bone alterations may be present 
in leprosy patients with none of the known risk factors 
of bone disease. There is still an extensive amount of 
unknown matters regarding this complication in lep-
rosy, as well as the role of PHEX in bone homeostasis 
that still need to be addressed. We looked into one of 
the possible mechanisms hoping to find an additional 
pathway that may help to explain bone disease physi-
opathology in leprosy.
Additional file
Additional file 1: Table S1. Clinical and laboratory findings of five LL 
patients.
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